Vesnarinone: a differentiation-inducing anti-cancer drug.

Abstract

Vesnarinone has been shown to be a unique anti-proliferating, differentiation-inducing and apoptosis inducing drug against several human malignancies, including leukemia and several solid tumors. Furthermore, vesnarinone potentiates the effect of conventional cytotoxic chemotherapy or radiation therapy. Combination of differentiation-inducing therapy by vesnarinone with conventional chemotherapy or radiation therapy might be second- or third-line therapy in patients with advanced cancer. Analysis of the molecular mechanisms of the tumor differentiation therapy by vesnarinone might provide selective and targeted molecules for novel tumor dormancy therapy.

• Authors: Hitoshi Kawamata, Fumie Omotehara, Koh-ichi Nakashiro, Daisuke Uchida, Satoshi Hino, Takahiro Fujimori
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 14 Issue 6 Pg. 391-5 (Jul 2003) ISSN: 0959-4973 [Print] England
• PMID: 12853878 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Pyrazines
• Quinolines
• Repressor Proteins
• TSC22D1 protein, human
• Tgfb1i4 protein, mouse
• vesnarinone

Topics

• Animals
• Antineoplastic Agents (chemistry, therapeutic use)
• Apoptosis (drug effects)
• Humans
• Mice
• Neoplasms (drug therapy, radiotherapy)
• Pyrazines
• Quinolines (chemistry, therapeutic use)
• Repressor Proteins (genetics, isolation & purification)